Boston Scientific's Strong Japanese Sales Help Offset U.S., EU Declines
This article was originally published in The Gray Sheet
Executive Summary
Emerging stent and balloon markets in Japan gave Boston Scientific its fourth consecutive quarter of market leadership in those businesses, as revenues grew 47% over the fourth quarter of 1998, the firm reported during a Feb. 8 teleconference.
You may also be interested in...
Boston Scientific NIR Stent With SOX Inventory Sufficient For Relaunch
Boston Scientific has sufficient inventory of its modified NIR coronary stent with the SOX delivery system to support relaunch the week of March 20, the firm reported March 16 in announcing FDA approval of a premarket approval application supplement. Product manufacturing and shipments to Japan commenced earlier this year following approval by the Japanese Ministry of Health in December.
Boston Scientific NIR Stent With SOX Inventory Sufficient For Relaunch
Boston Scientific has sufficient inventory of its modified NIR coronary stent with the SOX delivery system to support relaunch the week of March 20, the firm reported March 16 in announcing FDA approval of a premarket approval application supplement. Product manufacturing and shipments to Japan commenced earlier this year following approval by the Japanese Ministry of Health in December.
Boston Scientific To Report Q3 Results By Nov. 14 Despite Japan Difficulties
The detection of $40-50 mil. in improperly recorded sales in 1998 by Boston Scientific's Japan subsidiary is bittersweet testimony to the effectiveness of the firm's recently installed corporate SAP computer system.